New drug combination for blood cancers with TP53 changes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether combining a new drug called ATRN-119 with a cancer medicine called decitabine can help patients with acute myeloid leukemia (AML) or a related bone marrow condition called high-risk myelodysplastic syndrome (MDS), especially those whose cancer cells have changes in a gene called TP53. The trial is looking for patients who have not responded to or cannot tolerate standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AML or high-risk MDS based on specific bone marrow test results
- For the main trial phase: your cancer cells have a TP53 genetic change (mutation, deletion, or protein change) confirmed by testing
- You are at least 18 years old and able to care for yourself with minimal assistance (ECOG score of 2 or better)
- Your liver and kidney function are adequate enough to handle the study drugs
- You are willing to use birth control for 6 months after finishing the study drugs if you can become pregnant or father children
- You have not received previous treatment for your blood cancer (except certain supportive care like growth factors or hydroxyurea)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (axatilimab, decitabine, and venetoclax) for people with a specific type of acute myeloid leukemia (AML) that has a change in the TP53 gene. The goal is to see if this treatment can help when standard treatments haven't worked or for newly diagnosed patients with this genetic change.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.